Vasomotor Symptoms - Pipeline Insight, 2021

Vasomotor Symptoms - Pipeline Insight, 2021

  • May 2021 •
  • 60 pages •
  • Report ID: 5982687 •
  • Format: PDF
“Vasomotor Symptoms - Pipeline Insight, 2021,” report provides comprehensive insights about 9+ companies and 9+ pipeline drugs in Vasomotor Symptoms pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

Vasomotor Symptoms Understanding

Vasomotor Symptoms: Overview
Vasomotor symptoms (VMS), commonly called hot flashes or flushes (HFs) and night sweats, are considered as the cardinal symptoms of menopause. VMS are a form of temperature dysfunction that occurs due to changes in gonadal hormones. Vasomotor symptoms includes hot flashes, night sweats, heart palpitations, and changes in blood pressure. Most women experience hot flashes for 6 months to 2 years, although some women have them for 10 years or longer. Hot flashes occur in approximately 75 to 80 percent of menopausal women in the United States. Hormone therapy, antidepressant drugs and lifestyle modification are ways to manage vasomotor symptoms. Lifestyle modifications, including reducing core body temperature, regular exercise, weight management, smoking cessation, and avoidance of known triggers such as hot drinks and alcohol, may be recommended to reduce mild vasomotor symptoms.

"Vasomotor Symptoms - Pipeline Insight, 2021" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Vasomotor Symptoms pipeline landscape is provided which includes the disease overview and Vasomotor Symptoms treatment guidelines. The assessment part of the report embraces, in depth Vasomotor Symptoms commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Vasomotor Symptoms collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Vasomotor Symptoms R&D. The therapies under development are focused on novel approaches to treat/improve Vasomotor Symptoms.

Vasomotor Symptoms Emerging Drugs Chapters
This segment of the Vasomotor Symptoms report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Vasomotor Symptoms Emerging Drugs
• Donesta: Mithra Pharmaceuticals
Donesta (Estetrol) is an estrogen based drug candidate as a new generation of Hormone Therapy. Mithra Pharmaceuticals is currently evaluating Estetrol (E4) in Phase III clinical studies as an oral therapy for Vasomotor Menopausal Symptoms (VMS) relief.

• Q-122: QUE Oncology
Q-122 is an orally available small molecule based CXCR4 receptor antagonists. It is currently being studied in Phase II developmental studies for the treatment of hot flashes in women diagnosed with breast cancer who are receiving hormonal therapy.
Further product details are provided in the report……..

Vasomotor Symptoms: Therapeutic Assessment
This segment of the report provides insights about the different Vasomotor Symptoms drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Vasomotor Symptoms
There are approx. 9+ key companies which are developing the therapies for Vasomotor Symptoms. The companies which have their Vasomotor Symptoms drug candidates in the most advanced stage, i.e. Phase III include, Mithra Pharmaceuticals.

• Phases
This report covers around 9+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration
Vasomotor Symptoms pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical

• Molecule Type
Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Vasomotor Symptoms: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Vasomotor Symptoms therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Vasomotor Symptoms drugs.

Vasomotor Symptoms Report Insights
• Vasomotor Symptoms Pipeline Analysis

• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Vasomotor Symptoms Report Assessment
• Pipeline Product Profiles

• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Vasomotor Symptoms drugs?
• How many Vasomotor Symptoms drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Vasomotor Symptoms?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Vasomotor Symptoms therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Vasomotor Symptoms and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players
• Mithra Pharmaceuticals
• Acer Therapeutics
• QUE Oncology
• Bayer
• Endoceutics
• Astellas Pharma
• Mitsubishi Tanabe Pharma
• MenoGenix

Key Products
• Donesta
• Osanetant
• Q-122
• Elinzanetant
• Acolbifene + prasterone
• Fezolinetant
• Elismetrep
• Filgrastim